Despite improvements in recruitment of Latina medical students, the percentage of Latina physicians has remained stagnant, suggesting unique barriers to retention and career advancement. This is the …
Orca-Q led to low rates of graft-vs-host disease and non-relapse mortality in high-risk hematologic malignancies undergoing allo-HCT.
Dostarlimab received breakthrough therapy designation from the FDA for locally advanced dMMR/MSI-H rectal cancer.
Johnson & Johnson has submitted a type II variation application to the EMA seeking the approval of ibrutinib plus R-CHOP in ASCT-eligible frontline MCL.
Maximilian Stahl, MD, discusses unmet needs in relapsed/refractory AML, highlighting the potential utility menin inhibitors in select populations.
Small retrospective study showed that the procedure achieved negative surgical margins in all cases, with no patients requiring salvage cystectomy.
Long-term data from ZUMA-2 displayed durable responses with brexu-cel in relapsed/refractory mantle cell lymphoma.
2024 Most Read Articles | Blood Advances | American Society of Hematology Top Ten Most Read Articles in 2024 Blood Advances is pleased to announce…
After five years of follow-up in the phase 3 SEQUOIA study, first-line zanubrutinib treatment continues to demonstrate an improvement in progression-free survival in CLL versus…
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
FY25 FDA Broad Agency Announcement – Question and Answer Session
